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Abstract 
Background: Acute-on-chronic liver failure (ACLF) is a form of liver disease with high short-term mortality. ACLF 
offers considerable potential to affect the cortical areas by significant tissue injury due to loss of neurons and other 
supporting cells. We measured changes in cortical thickness and metabolites profile in ACLF patients following treat-
ment, and compared it with those of age matched healthy volunteers.
Methods: For the cortical thickness analysis we performed whole brain high resolution T1-weighted magnetic 
resonance imaging (MRI) on 15 ACLF and 10 healthy volunteers at 3T clinical MR scanner. Proton MR Spectroscopy (1H 
MRS) was also performed to measure level of altered metabolites. Out of 15 ACLF patients 10 survived and under-
went follow-up study after clinical recovery at 3 weeks. FreeSurfer program was used to quantify cortical thickness 
and LC- Model software was used to quantify absolute metabolites concentrations. Neuropsychological (NP) test was 
performed to assess the cognitive performance in follow-up ACLF patients compared to controls.
Results: Significantly reduced cortical thicknesses in multiple brain sites, and significantly decreased N-acetyl 
aspartate (NAA), myo-inositol (mI) and significantly increased glutamate/glutamine (glx) metabolites were observed 
in ACLF compared to those of controls at baseline study. Follow-up patients showed significant recovery in cortical 
thickness and Glx level, while NAA and mI were partially recovered compared to baseline study. When compared to 
controls, follow-up patients still showed reduced cortical thickness and altered metabolites level. Follow-up patients 
had abnormal neuropsychological (NP) scores compared to controls.
Conclusions: Neuronal loss as suggested by the reduced NAA, decreased cellular density due to increased cerebral 
hyperammonemia as supported by the increased glx level, and increased proinflammatory cytokines and free radicals 
may account for the reduced cortical thickness in ACLF patients. Presence of reduced cortical thickness, altered 
metabolites and abnormal NP test scores in post recovery subjects as compared to those of controls is associated 
with incomplete clinical recovery. The current imaging protocol can be easily implemented in clinical settings to 
evaluate and monitor brain tissue changes in patients with ACLF during the course of treatment.
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Background
Acute-on-chronic liver failure (ACLF) is a form of liver 
disease resulting in acute deterioration of liver function 
in patients with chronic liver disease and subsequently 
multiple organ failure over a period of weeks, and high 
short term mortality [1–3]. The prevalence of non-alco-
holic related ACLF is not well documented, however, it is 
reported that 9–32 % of Indian population have non-alco-
holic related fatty liver diseases with higher frequency in 
obese and diabetic patients, which is suggestive of higher 
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prevalence of ACLF in non-alcoholic liver diseases [4, 
5]. ACLF often presents with liver failure as the first evi-
dence of liver disease, manifested by serious complica-
tions and, subsequently, by hepatic encephalopathy (HE) 
[6, 7]. This syndrome is generally thought to result from 
neuronal dysfunction, diminished cerebral metabolism, 
morphological changes in astrocytes, and neuronal loss, 
leading to functional deficits of varying severity ranging 
from subtle minimal changes to severe coma [8–12].
ACLF offers considerable potential to affects the corti-
cal areas by significant tissue injury due to loss of neu-
rons and other supporting cells. Except for the nature of 
tissue changes and brain metabolites alteration, regional 
cortical thickness integrity in ACLF patients is unknown. 
Previously, reduced gray matter density and cortical 
thickness have been reported in chronic liver disease 
patients with minimal HE and history of overt HE [10, 
13–17]. So far, no study is available in other forms of liver 
failure such as in ACLF with severe HE. Precise determi-
nation of regional cortical thicknesses changes may assist 
evaluation of processes underlying the deficient func-
tional characteristics in ACLF patients.
Neuroimaging and proton MR spectroscopy (1H MRS) 
techniques have been used to characterize the brain tissue 
injury and altered cerebral metabolites in patients with 
ACLF [18–21]. A majority of patients with HE generally 
show no visible abnormalities on conventional magnetic 
resonance imaging (MRI), except for hyperintensities on 
T1-weighted images in the deep gray matter due to depo-
sition of manganese [22–24]. On diffusion tensor imag-
ing (DTI) studies, these patients have shown reduced 
fractional anisotropy (a marker of microstructural tis-
sue integrity), and altered mean diffusivity (indicator of 
water diffusion), in multiple brain areas, suggestive of 
the presence of abnormal tissue structures and cerebral 
edema [18]. On 1H MRS significantly decreased N-acetyl 
aspartate (NAA), myoinositol (mI) and increased glu-
tamate/glutamine (Glx) levels were observed in these 
patients [19]. Higher Glx levels in brain is associated with 
increased brain’s glutamine concentration which results 
from detoxification of ammonia and is associated with 
neuropsychological changes [25], while NAA is a marker 
of neuronal density/function, and mI provides informa-
tion about glial cells activation/proliferation [26].
Voxel based morphometric analyses have been used to 
quantify the brain’s structural changes in various patholo-
gies. The regional gray matter volume and tissue integrity 
assessed with voxel-based morphometric analysis may 
be influenced by analytical differences in extra-cortical 
cerebrospinal fluid and surface curvature/complexities. 
An alternative approach is to examine regional corti-
cal thicknesses, which can be performed with special-
ized software designed to quantify the regional cortical 
thickness changes, and such assessment is provided by 
FreeSurfer software [27].
In the current study, we aim to evaluate the regional 
cortical thicknesses and brain metabolites profiles in 
patients with ACLF in comparison with those of normal 
volunteers. We also assess the effect of conservative treat-
ment on cortical thickness and metabolites profile after 
clinical recovery in these patients. Since these patients 
have increased blood ammonia level and high oxidative 
stress due to end stage liver disease that can act as a neu-
rotoxin, we hypothesized that reduced cortical thickness 
and brain metabolites level would appear in ACLF over 
control subjects, especially in the cortical areas serving 
autonomic, motor, and cognitive functions, and that will 
improve after clinical recovery.
Methods
Participants
Institutional ethical committee approved the study proto-
cols. Informed consent was obtained from the nearest kin 
of all patients, as well as from individual controls, after 
explaining the nature and purpose of the MRI study. Fif-
teen patients with ACLF (males/females; 12/3, mean age 
42 ± 8.4 years) and 10 age/sex matched healthy controls 
(males/females; 8/2, mean age 39  ±  13.0  years) under-
went brain MRI, clinical and biochemical examination. 
Out of 15 patients, 10 patients underwent repeat brain 
MRI and cognitive assessment after clinical recovery at 
3  weeks of conservative treatment and were considered 
as clinically recovered. Demographic and clinical data 
of ACLF patients are summarized in Table 1. ACLF was 
diagnosed when there was evidence of an acute hepatic 
insult manifesting as jaundice and coagulopathy, compli-
cated within 4  weeks by ascites and/or encephalopathy 
in a patient with previously diagnosed or undiagnosed 
chronic liver disease [28]. West Haven criteria were used 
to grade the HE in these patients [29]. In order to estab-
lish the presence, severity, etiology and complications of 
the liver disease, blood tests including differential blood 
counts, liver and renal function tests, ascitic fluid exami-
nation, serologic tests for hepatotropic viruses, investiga-
tions for metabolic liver diseases and other investigations 
were performed. The exlusion criteria were as follows: 
patients with prior porta-systemic shunt surgery, prior 
neurological or psychiatric illness, active use of medi-
cations for psychiatric illnesses, significant alcohol 
intake (>40 gm/day in men, >20 gm/day in women) over 
6 months prior to imaging, ultrasonographic evidence of 
a mass lesion in the liver suggestive of hepatocellular car-
cinoma, biliary obstruction or suspected sepsis at pres-
entation and unsatisfactory image acquisition caused by 
motion artifacts. Both ACLF and control subjects were 
also excluded from the study if they were claustrophobic, 
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or carried non-removable metal, such as braces, embolic 
coils, pacemakers/implantable cardioverter-defibrillators, 
stents.
Neuropsychological (NP) test was performed to evalu-
ate cognitive functions in post recovery ACLF patients 
compared to controls. We performed a well-established 
trial making test and Wechsler Adult Intelligence Scale 
(WAIS)-P tests on these subjects, which can assess visual 
motor coordination, concentration, mental speed, mem-
ory and attention. We were unable to perform NP test at 
baseline study because these patients were encephalo-
pathic and unconscious.
Management protocol
All patients were managed according to a standard pro-
tocol, which includes close monitoring and meticulous 
optimization of all metabolic derangements [30]. Oxy-
genation was continuously monitored in each patient 
using pulse-oximeter and the blood glucose level was 
monitored 6-hourly using a glucometer. Vital param-
eters, neurological status and signs of raised intracranial 
pressure (ICP) were monitored 4-hourly. Aggressive cor-
rection of any hypoglycemia, hyponatremia or hypoka-
lemia was performed according to standard guidelines. 
Patients with ACLF who had clinical evidence of raised 
ICP received intravenous mannitol at a dose of 1–1.5 gm/
kg/24 h, divided into four boluses, for up to 48–72 h.
Magnetic resonance imaging data acquisition
All patients and controls underwent whole brain 
MRI on a 3.0 Tesla MR scanner (HDXT, Signa, 
General Electric technologies Systems, Milwaukee, 
WI) using an 8-channel head coil. Patients trans-
ported for MR imaging accompanied with a staff 
trained in resuscitation, critical care and with life-
support facilities on standby and ventilation sup-
port were started if they were unable to maintain 
atrial PaO2 >60  mmHg or SaO2 >90. None of the 
patients received any kind of sedation and/or mus-
cle paralyzing agents during imaging. Routine brain 
MRI studies including fast spin echo T2-weighted 
images with repetition time (TR)/echo time (TE)/
number of excitations (NEX)  =  5660  ms/98  ms/3, 
and T1-weighted fast spin echo images with TR/TE/
NEX  =  1950  ms/8.4  ms/1 were performed. High-
resolution T1-weighted brain images were also 
acquired using a fast spoiled gradient recalled echo 
(FSPGR) pulse sequence (TR = 8.4 ms; TE = 3.32 ms; 
inversion time  =  400  ms; flip angle  =  13°; matrix 
size = 512 × 512; field of view = 240 × 240 mm2; slice-
thickness =  1.0  mm) from each subject. 1H MRS was 
performed using single voxel point resolved spectros-
copy (PRESS) method with following parameters—TR/
TE = 3000 ms/35 ms and number of averages = 64. A 
voxel of 2 × 2 × 2 cm3 was placed mainly in the right 
basal ganglion region of the brain in all subjects. Both 
T1-, and T2-weighted images were examined for any 
gross brain pathology such as cysts, tumors, or any 
other mass lesions, and presence of such anomaly was 
used as an exclusion criteria. None of the patients and 
control subjects included in this study showed any 
major pathology.
Table 1 Characteristics and outcome of patients with acute-on-chronic liver failure
HBV hepatitis B virus, HEV hepatitis E virus, HCV hepatitis C virus, HE hepatic encephalopathy
Cases Age/sex Chronic etiology Acute etiology Grade  
of HE
Jaundice-HE  
interval (days)
Outcome
#1 45/F Cryptogenic HEV 2 3 Discharged
#2 41/M Cryptogenic HEV 2 4 Discharged
#3 48/M Cryptogenic HEV 2 4 Discharged
#4 50/M Wilson disease ATT 4 2 Discharged
#5 50/M HBV HBV 1 25 Discharged
#6 44/M Cryptogenic Unknown 2 20 Discharged
#7 30/M HBV HBV 2 4 Discharged
#8 35/F Cryptogenic HBV 3 4 Discharged
#9 50/F Cryptogenic HAV 3 3 Discharged
#10 50/M HBV HBV 2 2 Deceased
#11 32/M HCV HEV 4 9 Deceased
#12 35/M Cryptogenic HEV 4 14 Discharged
#13 25/M Cryptogenic Unknown 4 23 Deceased
#14 47/M Cryptogenic Unknown 3 12 Deceased
#15 48/M Cryptogenic Unknown 1 14 Deceased
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Measurements of cortical thicknesses
High-resolution T1-weighted brain images were used 
to measure the regional cortical thicknesses in all sub-
jects by applying cross sectional pipeline of FreeSurfer (v 
5.3.0), as described in detail elsewhere [27]. Briefly, high-
resolution T1-weighted brain images volumes from each 
subject were converted into FreeSurfer data format. Data 
processing included removal of non-brain tissue using a 
hybrid watershed/surface deformation procedure, auto-
mated Talairach transformation, intensity normalization, 
segmentation of sub-cortical white and deep gray mat-
ter tissue types, tessellation of the gray and white matter 
boundaries, automated topology correction, and surface 
deformation (http://surfer.nmr.mgh.harvard.edu/). To 
measure changes in the cortical thickness between base-
line and follow-up scans of ACLF patients, images were 
processed using the FreeSurfer longitudinal pipeline [31] 
(http://surfer.nmr.mgh.harvard.edu/fswiki/Longitudi-
nalProcessing). All subjects’ processed data were manu-
ally evaluated to ensure no brain areas were excluded. 
Similarly, gray, white, and pial boundaries were visually 
assessed, and if needed, edits were made to correct misi-
dentified regions. In most subjects, only minor edits were 
required to remove non-brain areas after automatically 
detected skull strip procedures.
1H-MR spectroscopy data processing
For evaluation and quantification of all individual spec-
tra, the LC- Model software package (Version 6.0) was 
used [32]. The absolute concentration of NAA, Glx, and 
mI were calculated.
Statistical analysis
Demographic and clinical variables
IBM Statistical Package for the Social Sciences (IBM 
SPSS, v 16, Chicago, IL, USA) was used for statistical 
analyses. Subjects’ demographic, clinical, and neuropsy-
chological profiles were assessed by independent sam-
ples t-tests and Chi square. One-way analysis of variance 
(ANOVA) was performed to compare 1H MRS derived 
metabolites levels in different study groups. A p  <  0.05 
value was considered statistically significant.
Regional cortical thicknesses
Gray matter surface maps were smoothed using a Gauss-
ian kernel (FWHM, 15 mm). Regional changes in cortical 
thicknesses among different groups were examined using 
a vertex-by-vertex general linear model, implemented in 
FreeSurfer, with regional cortical thicknesses modeled 
as a function of groups, and age and gender included 
as covariates in the analysis (ANCOVA; p  <  0.05, false 
discovery rate corrections for multiple comparisons). 
The statistical parametric maps with regional cortical 
thickness differences were generated separately for the 
left and right hemispheres. Clusters with significant dif-
ferences between groups were overlaid onto averaged 
inflated cortical surface maps for structural identification.
Results
Demographics
No significant differences were observed either in gender 
(p = 0.50) or age distribution (p = 0.38) among groups.
Clinical profile of ACLF patients
Clinical and biochemical profile of ACLF patients is sum-
marized in Table 1. The etiology of acute components in 
15 patients with ACLF was hepatitis A (n =  1), hepati-
tis B (n = 4), hepatitis E (n = 5), antituberculosis drugs 
(n = 1) and unknown (n = 4), and the etiology of chronic 
liver disease was hepatitis B (n = 3), hepatitis C (n = 1), 
Wilson disease (n = 1), and cryptogenic (n = 10). At the 
time of imaging, 4 patients were in grade IV, 3 patients in 
grade III, 6 patients in grade II and 2 patients in grade I 
encephalopathy (Table 1).
Cortical thicknesses findings in controls, baseline and post 
recovery ACLF patients
At baseline study, ACLF patients showed significantly 
decreased cortical thickness in multiple brain areas both 
in the left and right hemisphere compared to those of 
controls. Regions with decreased cortical thickness in the 
left hemisphere were rostral middle frontal, superior fron-
tal, pars triangularis, posterior cingulate, inferior tempo-
ral, lateral orbitofrontal, caudal middle frontal, precentral, 
entorhinal, superior temporal, inferior temporal, middle 
temporal, supramarginal, pars opercularis, supramarginal, 
pars opercularis, middle temporal, and inferior parietal 
(Table  2; Fig.  1), while in the right hemispheres these 
regions were- parahippocampal, rostral middle frontal, 
pars triangularis, lateral orbitofrontal, superior frontal, 
pars orbitalis, posterior cingulate, postcentral, precuneus, 
rostral middle frontal, superior temporal, precentral, 
superior frontal, caudal middle frontal, superior temporal 
(Table 2; Fig. 1). Only the lingual region in the left hemi-
sphere showed increased cortical thickness.
At 3  weeks of clinical recovery, these patients still 
showed decreased cortical thickness in few brain sites 
as compared to those of controls (Fig.  2). These areas 
include posterior cingulate, middle temporal, superior 
frontal regions in the left hemisphere (Table 3; Fig. 2) and 
paracentral, parahippocampal, lateral orbitofrontal, pos-
terior cingulate regions in the right hemispheres (Table 3; 
Fig. 2).
In follow-up study, significantly increased cortical 
thicknesses in lateral orbitofrontal, rostral middle fron-
tal, rostral middle frontal, rostral middle frontal, superior 
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frontal, lateral orbitofrontal regions in the left hemi-
sphere (Table 3; Fig. 3) and in entorhinal, superior frontal, 
rostral middle frontal, lateral orbitofrontal, pars triangu-
laris regions in the right hemisphere (Table 3; Fig. 3) were 
observed compared to those of baseline study. In follow-
up study, our longitudinal FreeSurfer processing pipeline 
reduced the chances of positioning variation during data 
processing.
Metabolites levels in controls, baseline and post recovery 
ACLF patients
At baseline, ACLF patients showed significantly 
decreased NAA (p  =  0.001) and mI (p  =  0.001), and 
increased Glx (p = 0.001) as compared to those of con-
trols (Table 4). At 3 weeks clinical recovery, these patients 
still showed significantly decreased NAA (p  =  0.004), 
and mI (p  =  0.001), and significantly increased Glx 
Table 2 Surface areas of significantly reduced cortical thickness in baseline ACLF over control from both hemispheres
Each area consists of adjacent voxels showing a significant group difference; some brain structures have more than one area of change. The magnitude of the peak (t 
statistic) in each area and its Tailarach coordinates (a standardized common brain space) are listed, together with the size (in normalized space) and the mean and SD 
of the cortical thickness for the control and baseline ACLF groups
L left, R right
Cluster no. Structures in area Max t-statistic Size (mm2) TalX TalY TalZ Cortical thickness 
(Mean ± SD)
Control Baseline
1 L Rostral middle frontal 6.48 965 −42.7 29.1 30.1 2.45 ± 0.10 2.17 ± 0.11
2 L Superior frontal 4.55 935 −9.6 63.2 13.7 2.66 ± 0.24 2.24 ± 0.16
3 L Pars triangularis 4.52 1251 −50.8 24.9 5.9 2.58 ± 0.13 2.29 ± 0.12
4 L Posterior cingulate 4.41 162 −10.9 −2.6 39.8 2.60 ± 0.13 2.35 ± 0.17
5 L Inferior temporal 4.31 536 −55.5 −33.2 −16.6 2.76 ± 0.17 2.48 ± 0.11
6 L Lateral orbitofrontal 4.16 284 −12.4 42.6 −21.9 2.16 ± 0.17 1.89 ± 0.11
7 L Caudal middle frontal 3.95 264 −42 2.4 48.5 2.65 ± 0.23 2.32 ± 0.13
8 L Precentral 3.67 229 −55.1 −3.2 38.8 2.69 ± 0.14 2.46 ± 0.10
9 L Entorhinal 3.59 75 −19.9 −14.2 −28.5 3.16 ± 0.18 2.80 ± 0.20
10 L Superior temporal 3.51 137 −63.5 −30.1 7.3 2.68 ± 0.15 2.40 ± 0.15
11 L Inferior temporal 3.51 454 −41.2 −0.2 −36.8 3.30 ± 0.25 2.81 ± 0.26
12 L Middle temporal 2.99 390 −51.2 −20.2 −14.8 2.64 ± 0.25 2.33 ± 0.13
13 L Supramarginal 2.80 35 −60 −26.8 21.2 2.54 ± 0.17 2.38 ± 0.13
14 L Pars opercularis 2.76 29 −34.7 12.7 24.4 2.22 ± 0.17 2.01 ± 0.10
15 L Supramarginal 2.63 11 −52.2 −47 43.9 2.63 ± 0.18 2.38 ± 0.16
16 L Pars opercularis 2.59 15 −44.2 5.2 7.8 2.67 ± 0.15 2.49 ± 0.15
17 L Middle temporal 2.59 18 −56.4 −7.9 −27.8 3.08 ± 0.24 2.78 ± 0.17
18 L Lingual −2.58 21 −7.4 −68.3 −0.3 1.71 ± 0.13 1.97 ± 0.23
19 L Inferior parietal 2.54 5 −39.7 −68.5 35.1 2.45 ± 0.12 2.23 ± 0.17
1 R Parahippocampal 5.74 191 23.3 −23.6 −23.2 2.93 ± 0.17 2.48 ± 0.16
2 R Rostral middle frontal 5.29 537 35.9 45.7 21.6 2.27 ± 0.06 2.01 ± 0.12
3 R Pars triangularis 5.19 888 54.3 26.1 9.1 2.63 ± 0.09 2.32 ± 0.14
4 R Lateral orbitofrontal 4.96 402 15.5 35.5 −24 2.24 ± 0.17 1.94 ± 0.11
5 R Superior frontal 4.45 270 17.7 38.7 42.2 2.54 ± 0.08 2.27 ± 0.14
6 R Pars orbitalis 3.92 728 40.2 51 −7.2 2.53 ± 0.16 2.13 ± 0.22
7 R Posterior cingulate 3.84 94 9.7 −1.6 41.2 2.65 ± 0.18 2.36 ± 0.12
8 R Postcentral 3.44 121 61.5 −9.7 30.5 2.46 ± 0.14 2.17 ± 0.16
9 R Precuneus 3.44 88 7.4 −60.7 57.3 2.37 ± 0.16 2.11 ± 0.17
10 R Rostral middle frontal 3.45 725 23.1 54.6 21.1 2.30 ± 0.16 2.05 ± 0.15
11 R Superior temporal 3.41 263 51.6 −18.1 −5.4 2.77 ± 0.21 2.47 ± 0.15
12 R Precentral 2.91 60 50.4 −0.1 41.4 2.72 ± 0.22 2.41 ± 0.17
13 R Superior frontal 2.90 65 7.9 37.4 42.5 2.81 ± 0.19 2.51 ± 0.21
14 R Caudal middle frontal 2.83 21 31 13.9 47.8 2.46 ± 0.12 2.25 ± 0.16
15 R Superior temporal 2.73 29 49.8 6.3 −16.9 3.22 ± 0.33 2.74 ± 0.32
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(p = 0.030) levels than those of controls (Table 4). When 
compared to baseline metabolites level, only Glx level 
was significantly decreased (p  =  0.024) in follow-up 
patients (Table 4).
Neuropsychological findings in controls and post recovery 
ACLF patients
Neuropsychological tests were performed in controls 
and in follow-up ACLF patients after clinical recovery. 
Follow-up ACLF patients showed significantly higher NP 
tests score for trial making test (number connection test 
(NCT)-A, p = 0.002; NCT-B, p = 0.001; figure connec-
tion test (FCT)-A, p =  0.004 and p =  0.006) and lower 
NP tests score for Wechsler Adult Intelligence Scale 
(WAIS)-P (picture completion (PC), p = 0.001; digit sym-
bol (DS), p = 0.001; block design (BD), p = 0.001; picture 
assembly (PA =  , p =  0.001 and object assembly (OA), 
p = 0.003) compared to those of healthy controls (Fig. 4).
Discussion
In the current study, decreased cortical thickness was 
detected in multiple brain areas in ACLF patients com-
pared to those of controls, suggesting loss of gray matter 
tissues. These cortical areas regulate various cognitive, 
autonomic, language, visual sensory and motor functions 
that are deficient in ACLF patients. The pathological pro-
cesses contributing to the altered regional cortical thick-
ness may be due to increased cerebral hyperammonemia, 
Fig. 1 Brain regions showing significantly reduced cortical thickness in baseline ACLF patients compare to control subjects in the left hemispheres 
overlaid on inflated pial surface, include rostral middle frontal (1), superior frontal (2), pars triangularis (3), posterior cingulate (4), inferior temporal 
(5), lateral orbitofrontal (6), caudal middle frontal (7), precentral (8), entorhinal (9), superior temporal (10), inferior temporal (11), middle temporal 
(12), supramarginal (13), pars opercularis (14), supramarginal (15), pars opercularis (16), middle temporal (17), lingual (18), and inferior parietal (19) 
and right hemispheres include parahippocampal (1), rostral middle frontal (2), pars triangularis (3), lateral orbitofrontal (4), superior frontal (5), pars 
orbitalis (6), posterior cingulate (7), postcentral (8), precuneus (9), rostral middle frontal (10), superior temporal (11), precentral (12), superior frontal 
(13), caudal middle frontal (14), and superior temporal (15)
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proinflammatory cytokines and free radicals result-
ing from diminished liver function and/or secondary to 
infection. Reduced cortical thickness in patients with 
ACLF can be better explained by the ex vivo histopatho-
logical analysis. Though, no brain histopathological study 
is available on ACLF patients, while one brain histo-
pathological study in cirrhotic patients with end-stage-
liver disease with and without alcoholic etiology showed 
brain atrophy and Alzheimer’s type II astrocytosis [33]. 
We suggest that decreased cortical thickness in ACLF 
patients may have similar brain changes, a contention 
that needs to be validated on animal models of ACLF and 
that opens an inquisitive area of research.
The current findings in ACLF patients are consistent 
with the previous MRI finding in patients with liver dis-
ease associated with minimal HE and history of overt 
HE, which showed decreased gray matter density and 
cortical thickness in various brain sites [10, 13–15]. 
Chen et al., have showed decreased grey matter volume 
in many cortical areas in cirrhotic patients with a his-
tory of overt HE [10] and suggested that the presence of 
Alzheimer type II astrocytosis in gray matter and a dif-
fuse spongy degeneration of cortex might be responsible 
for neuronal damage and lead to gray matter atrophy. 
Another study performed by Guevara et al., using voxel 
based morphometric analysis observed reduced regional 
gray and white matter areas in multiple brain sites 
including cingulate, precuneus, temporal, occipital lobes 
and precentral in cirrhotic patients [34]. Earlier, stud-
ies based on DTI and 1H MRS have showed significant 
abnormality in DTI metrics as well as metabolites level 
in patients with ACLF [18–21]. It has been suggested 
that the loss of neuronal and glial cells are responsible 
for these changes.
Fig. 2 Brain regions showing significantly reduced cortical thickness in ACLF post recovery over control subjects in the left hemispheres overlaid 
on inflated pial surface, include posterior cingulate (1), middle temporal (2), and superior frontal (3) and right hemispheres include paracentral (1), 
parahippocampal (2), lateral orbitofrontal (3), and posterior cingulate (4)
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Table 3 Surface areas of significantly reduced CT in ACLF post-recovery over control and increased CT in post-recovery 
over baseline from both hemispheres
Each area consists of adjacent voxels showing a significant group difference; some brain structures have more than one area of change. The magnitude of the peak (t 
statistic) in each area and its Tailarach coordinates (a standardized common brain space) are listed, together with the size (in normalized space) and the mean and SD 
of the cortical thickness for control and post recovery ACLF group. And baseline and post recovery ACLF group
CT cortical thickness, L left, R right
Cluster No. Structures in area Max t statistic Size (mm2) TalX TalY TalZ Thickness (mm), mean ± SD
Control Post ACLF
1 L Posterior cingulate 5.392 79 −5.8 −13.9 39.2 2.77 ± 0.19 2.63 ± 0.16
2 L Middle temporal 4.887 196 −45.6 3.8 −34.3 3.27 ± 0.23 2.99 ± 0.21
3 L Superior frontal 4.768 62 −11 14 45.6 2.59 ± 0.16 2.54 ± 0.23
1 R Paracentral 5.153 166 10.1 −15.5 48.9 2.44 ± 0.12 2.42 ± 0.21
2 R Parahippocampal 4.928 59 25.2 −20.9 −27.3 3.20 ± 0.31 3.03 ± 0.22
3 R Lateral orbitofrontal 4.671 50 30.4 28.9 −2.4 2.72 ± 0.12 2.62 ± 0.23
4 R Posterior cingulate 3.926 17 5.1 −12.5 39.4 2.65 ± 0.13 2.64 ± 0.24
Cluster no. Structures in area Max t statistic Size (mm2) TalX TalY TalZ Thickness (mm), mean ± SD
Baseline ACLF Post ACLF
1 L Lateral orbitofrontal −2.745 577 −29 50.8 −10.9 2.08 ± 0.15 2.33 ± 0.15
2 L Rostral middle frontal −2.632 93 −37.1 43.4 0.3 1.95 ± 0.12 2.12 ± 0.11
3 L Rostral middle frontal −2.244 25 −38.6 26.5 35.6 2.25 ± 0.10 2.35 ± 0.09
4 L Rostral middle frontal −2.210 43 −33.9 32.4 29.5 2.06 ± 0.12 2.24 ± 0.14
5 L Superior frontal −2.204 59 −8.1 62.2 16.9 2.25 ± 0.16 2.50 ± 0.17
6 L Lateral orbitofrontal −2.013 4 −35.9 25.6 −17.7 2.31 ± 0.18 2.51 ± 0.12
1 R Entorhinal −3.97 185 21 −11.2 −29.2 2.89 ± 0.22 3.37 ± 0.22
2 R Superior frontal −2.313 71 8.3 58.1 26.5 2.29 ± 0.18 2.53 ± 0.15
3 R Rostral middle frontal −2.232 74 19.7 57 17.6 2.06 ± 0.21 2.30 ± 0.12
4 R Lateral orbitofrontal −2.086 36 17.1 39.4 −18.9 2.04 ± 0.14 2.26 ± 0.20
5 R Pars triangularis −2.0108 2 54.3 25.6 10.1 2.30 ± 0.14 2.50 ± 0.17
Fig. 3 Brain regions with scatter plots showing significantly increased cortical thickness in post recovery compare to baseline in the left hemi-
spheres overlaid on inflated pial surface, include lateral orbitofrontal, rostral middle frontal, rostral middle frontal, rostral middle frontal, superior 
frontal, and Lateral orbitofrontal and right hemispheres, include entorhinal, superior frontal, rostral middle frontal, lateral orbitofrontal, and pars 
triangularis
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HE is a diffuse brain disease and influences all brain 
structures including both gray and white matter as 
well as deep brain structures such as basal ganglia [11, 
13, 14, 16–19, 35]. Cortical structures and the lim-
bic system structures (i.e. basal ganglia) interact via 
a relatively well understood and elaborate system of 
interconnections and damage to the basal ganglia can 
produce many of the same cognitive impairments as 
damage to the other cortical structures [36]. We sug-
gest that any changes in metabolites levels in basal 
gangalia would also reflect the metabolites changes in 
other cortical areas. In the current study, spectroscopic 
information from basal ganglia is used as a proxy to 
explain the plausible mechanistic pathway for cortical 
thickness changes in ACLF patients. On 1H-MR spec-
troscopy ACLF patients showed significantly decreased 
NAA, and mI while increased Glx, as compared to 
those of controls [19]. Since NAA and mI are markers 
of neuronal and glial cells, respectively, the decreased 
concentration of these metabolites in ACLF suggests 
the contribution of decreased neuronal and glial cells 
density in cortical thickness loss. It has been reported 
that ammonia plays a key role in the pathogenesis of 
HE [10, 34]. Previous studies have demonstrated a cor-
relation between altered brain metabolism and blood 
ammonia level in cirrhotic patients as well as in ani-
mal model [37–39]. Significantly increased brain Glx in 
ACLF patients, as observed in the current study as well 
as previous studies, reflects the increased ammonia 
level due to liver failure and this may initiate a cascade 
for the reduced cortical thickness in these patients. A 
study performed by Odeh et  al., observed that TNF-α 
positively correlates with ammonia in patients with 
chronic liver disease [40] and supports the hypothesis 
of ammonia being a factor for the pathogenesis of HE 
[41, 42]. Cauli et al., have showed that proinflammatory 
cytokines may alter the blood brain barriers (BBBs) 
and influence the synthesis of nitric oxides in astro-
cytic cells, resulting in increased diffusion of ammo-
nia into the brain and subsequent development of HE 
and brain tissue loss [43]. Recently, a number of studies 
have demonstrated that during HE, ammonia impairs 
BBBs permeability by generating excessive oxidative/
nitrosative stress directly within the endothelial cells 
leading to activation of the matrix metalloproteinases 
and to increased paracellular passage of proteins [44, 
45]. In ACLF patients significantly increased blood 
ammonia and inflammatory cytokines may synergisti-
cally responsible for the reduced cortical thickness in 
Table 4 Mean and standard deviation of metabolites level 
in ACLF (baseline) compared to controls and follow−up
NAA N-acetyl aspartate, mI myo inositol, Glx glutamine/glutamate
Groups Metabolites (mmol/kg)
NAA MI Glx
Control (a) 12.9 ± 1.30 2.60 ± 0.50 15.0 ± 2.50
Baseline (b) 10.9 ± 1.15 1.40 ± 0.69 22.5 ± 5.41
Follow−up (c) 11.2 ± 1.00 1.72 ± 0.41 18.1 ± 3.62
p-values
 a vs b a − b = 0.001 a −b = 0.001 a − b = 0.001
 a vs c a − c = 0.004 a − c = 0.001 a − c = 0.030
 b vs c b − c = 0.424 b − c = 0.184 b − c = 0.024
Fig. 4 On bar graphs control subjects are showing significantly lower trail making test scores (NCT-A,B and FCT-A,B) and higher WAIS-P test scores 
(PC, DS, BD, PA and OA) as compared to post recovery ACLF after 3 weeks of conservative therapy
Page 10 of 12Yadav et al. J Transl Med  (2015) 13:322 
multiple brain sites. Further studies are required to 
explore the relationship between the regional reduction 
in cortical thickness, blood ammonia level and proin-
flammatory cytokines in these patients.
Follow-up study
All the brain regions, which showed significantly 
decreased cortical thickness at baseline were tend to 
reversible in follow-up study. Only few brain regions 
showed significantly lower cortical thickness compared to 
those of controls. The other brain regions, which appear 
to be recovered, still showed non-significantly decreased 
cortical thickness in follow-up patients when compared 
to those of controls (data not shown). In post recovery 
group, partial recovery in NAA, and mI and significant 
recovery in Glx were observed compared to baseline, 
indicating a positive metabolic outcome in these patients 
in response to conservative treatment. However, com-
pared to controls, they still showed significant differences 
in these metabolites levels. Incomplete normalization of 
1H-MR spectroscopy profile in follow up study suggests 
that metabolic recovery lags behind the clinical recovery, 
and results also suggest that cortical thickness is a much 
more sensitive marker of clinical recovery.
Post recovery patients showed abnormal NP tests score 
as compared to healthy controls, suggesting persistence 
of abnormal cognitive functions which is consistent with 
previous study in overt HE [46, 47]. The abnormal NP test 
score in the follow-up patients can be explained based on 
the reduced cortical thickness in various brain regions, 
as well incomplete recovery of metabolites level. It has 
been proposed that systemic inflammatory response 
exacerbates the neuropsychological alterations induced 
by hyperammonemia and that the change in neuropsy-
chological functions following induced hyperammone-
mia is greater in those with more severe inflammation 
[48]. Presence of reduced cortical thickness and impaired 
cognitive functions in post recovery as compared to con-
trol, demonstrates that brain dysfunction induced by HE 
persisted after clinical resolution and provided a basis for 
further evolution of the disease.
Thiamine deficiency has been shown to occur in patients 
with liver diseases due to impaired metabolism and stor-
age, decreased liver cell mass, along with decreased intake 
and poor absorption that results from chronic conges-
tion in the mesenteric venous system. It has been dem-
onstrated that reduced thiamine level influence the brain 
microstructures in ACLF patients and recovered after oral 
supplementation of thiamine [20]. A study on rat animal 
model of thiamine deficiency showed recovery in brain 
neuronal damage following intraperitoneal supplementa-
tion of thiamine [49]. Since all the ACLF patients enrolled 
in the current study received oral supplementation of thia-
mine as a part of their conservative treatment we suggest 
that improved liver functions secondary to thiamine may 
be responsible for the recovery of cortical thickness and 
metabolietes levels in ACLF patients.
It is important to mention some of the limitations 
of the current study, which include limited number of 
subjects, short duration of follow-up period, and lack 
of quantification of thiamine and ammonia levels in the 
blood.
Conclusions
Significantly reduced cortical thicknesses appeared in 
ACLF over controls in both brain hemispheres including 
frontal, parietal, temporal and occipital lobes. These multi-
ple brain sites are involved in regulating various functions 
including cognitive, autonomic, language, visual sensory 
and motor functions. We suggest that neuronal loss and 
decreased cellular density due to increased cerebral hyper-
ammonemia, proinflammatory cytokines and free radicals 
might be possible reasons for the reduced regional cortical 
thickness in these patients. Presence of reduced regional 
cortical thickness, altered metabolites and NP test scores 
in post recovery subjects as compared to controls suggest 
incomplete recovery over clinical characteristics. Further 
study in the animal model may be useful to assess this cor-
relation, and may provide more accurate explanation for 
the reduced cortical thickness. Nevertheless, the current 
method can be easily implemented on clinical scanner to 
evaluate and monitor the brain tissue changes in patients 
with liver failure during the course of treatment.
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